Key result
Micronized fenofibrate administration in hypertriglyceridemic patients significantly reduced serum levels of C-reactive protein by 34%, fibrinogen by 9.5%, and plasma PAF-AH by 24.8%.
Why the study?
Does micronized fenofibrate reduce serum inflammatory markers in patients with high triglyceride values?
Does micronized fenofibrate reduce serum inflammatory markers in patients with high triglyceride values?
Fenofibrate significantly reduces inflammatory markers such as CRP, fibrinogen, and PAF-AH in hypertriglyceridemic patients, suggesting anti-inflammatory properties that may contribute to its antiatherogenic effects.
No takes yet. Share an insight, caveat, or question.
Fenofibrate was associated with reduced inflammatory markers in hypertriglyceridemia; hypothesis-generating for cardiovascular benefit, pending randomized trials.
Tsimihodimos et al. (2004) studied Hypertriglyceridemia (n=58). Micronized fenofibrate was evaluated on Serum inflammatory markers (C-reactive protein, fibrinogen, and plasma PAF-AH). Micronized fenofibrate administration in hypertriglyceridemic patients significantly reduced serum levels of C-reactive protein by 34%, fibrinogen by 9.5%, and plasma PAF-AH by 24.8%.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: